

# Asymmetric Synthesis of Pyrido[1,2-*c*]pyrimidinones

Jörg Pabel<sup>a</sup>, Elmar Wadenstorfer<sup>b</sup>, and Klaus T. Wanner<sup>a</sup>

<sup>a</sup> Department of Pharmacy, Center of Drug Research, Ludwig-Maximilians-University Munich, Butenandtstraße 5–13, 81377 Munich, Germany

<sup>b</sup> Daiichi Sankyo Europe GmbH, Luitpoldstr. 1, 85276 Pfaffenhofen, Germany

Reprint requests to Prof. Dr. K. T. Wanner. Fax: +49 89 2180 77247.

E-mail: Klaus.Wanner@cup.uni-muenchen.de

Z. Naturforsch. 2009, 64b, 653–661; received April 16, 2009

Dedicated to Professor Gerhard Maas with best wishes on the occasion of his 60<sup>th</sup> birthday

“Asymmetric Electrophilic  $\alpha$ -Amidoalkylation” reactions with a chiral alkylaminocarbonyl unit as chiral auxiliary are used for the stereoselective synthesis of 2-substituted piperidine derivatives. Intramolecular condensation of the nitrogen of the aminocarbonyl group with the keto function present in the newly introduced side chain of the amidoalkylation products results in the formation of hexahydropyrido[1,2-*c*]pyrimidinones. After reduction and removal of the *N*-alkyl moiety of the chiral auxiliary the target compounds, enantiopure octahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-ones, are obtained.

**Key words:**  $\alpha$ -Amidoalkylation, Asymmetric Synthesis, Heterocycles, *N*-Acyliminium Ion, Pyridopyrimidinone

## Introduction

The piperidine ring is a common structure in many natural products [1] and is found in numerous biologically active compounds [2]. Accordingly, the synthesis of isolated as well as fused piperidine derivatives has represented a field of intense research efforts for many decades with increasing attention being paid to methods providing access to enantiopure compounds [3].

Previously, we reported on a cationic type of asymmetric synthesis involving chiral *N*-acyliminium ions provided with an *N*-acyl group as chiral auxiliary [4]. This methodology, which we termed “Asymmetric Electrophilic  $\alpha$ -Amidoalkylation” (AE $\alpha$ A), has been successfully employed in the stereoselective synthesis of  $\alpha$ -substituted piperidines [5], pyrrolidines [6], 1,2,3,4-tetrahydroisoquinolines [7], and 1,2,3,4-tetrahydro- $\beta$ -carboline [8]. Further efforts aimed at extending this concept to iminium ions **1** (Scheme 1) in which a chiral *N*-alkylaminocarbonyl






Fig. 1. Tetraponerines T3, T4, T7 and T8.

substituent instead of a chiral *N*-acyl group serves as a chiral auxiliary. The successful implementation of this plan was expected to give access to the alkylation products **2** (Scheme 1) which in turn should be suitable starting materials for the preparation of stereoisomeric pyrido[1,2-*c*]pyrimidinones **3** and **4** in enantiopure form (Scheme 1). As pyrido[1,2-*c*]pyrimidinones **3** and **4** are structurally related to the tetraponerines T3, T4, T7 and T8 (Fig. 1), toxic alkaloids found in the New Guinean ant Tetraponera sp., the realization of



Scheme 1.



Scheme 2.

the aforementioned synthetic concept seemed highly rewarding [9].


Interestingly, amidoalkylation reactions of this type with the asymmetric induction arising from acyclic stereocontrol utilizing an alkylaminocarbonyl group are still unprecedented for piperidine so far. The only related study has been published by Streith *et al.* [10]. They successfully used the oxazolidinone **5** to generate the chiral pyridinium ion **6**, which when treated with  $\text{RMgBr}$  yielded the dihydropyridone **7** (Scheme 2).

## Results and Discussion

We selected the piperidine derivatives **13** and **16** as amidoalkylation reagents for this study (Scheme 4). The enamide moiety present in **13** and **16** was intended to serve as a precursor for the generation of acyliminium ions, for which purpose it had often been used in previous studies [11]. The (*S*)-1-phenyl-1-ethylaminocarbonyl and the (*S*)-1-naphthyl-1-ethylaminocarbonyl moieties in **13** and **16** had been chosen as chiral auxiliaries as the commercial availability of the isocyanates (*S*)-1-(1-isocyanatoethyl)benzene (**8**) and (*S*)-1-(1-isocyanatoethyl)naphthalene (**11**) (Scheme 3) was expected to facilitate the synthesis of the required piperidine derivatives.

The synthesis of the enamides **13** and **16** was performed as outlined in Scheme 3. Upon treatment of 1,2,3,6-tetrahydropyridine **9** with either (*S*)-1-(1-isocyanatoethyl)benzene (**8**) or (*S*)-1-(1-isocyanatoethyl)naphthalene (**11**) the tetrahydropyridine derivatives **10** and **12** were obtained, in 91 % and 94 % yield, respectively.

Subsequent isomerization of the allyl amides **10** and **12** employing Pd on  $\gamma\text{-Al}_2\text{O}_3$  as catalyst in the presence of triethylamine led to the corresponding enamides **13** and **16** in 82 % and 68 % yield, respectively (Scheme 4). For analogous isomerization reactions reported previously [11a] Pd on carbon had been used as a catalyst. In the case of **10** and **12**, however, distinctly higher yields were reached when Pd




Scheme 3.

on  $\gamma\text{-Al}_2\text{O}_3$  instead of Pd on carbon was employed as catalyst.

For the amidoalkylation reactions, enamides **13** and **16** were activated following a common procedure developed for related compounds. Thus  $\text{CH}_2\text{Cl}_2$  was saturated with a large excess of HCl gas, and the enamides **13** and **16** were added to this solution. Then, after vacuum had been applied to remove unbound HCl,  $\text{TiCl}_4$  was added to transform the presumed intermediates, the  $\alpha$ -chloroamides **14** and **17**, into the corresponding *N*-acyliminium ions **15** and **18** (Scheme 4).

When silylenolether **19** selected as trapping reagent was added to the reaction mixture that had been generated as described above, the expected addition products, **20/21** and **22/23**, were indeed formed, but the yields for the addition products **20/21** (34 %) and **22/23** (50 %) were far from being satisfying, and also the stereoselectivity was low (**20/21** = 60/40; **22/23** = 78/22). For both the poor yield and low selectivity HCl gas was blamed that despite evacuation might have remained in the reaction solution. Therefore, in further experiments in contrast to the original procedure instead of a large excess a definite amount of HCl gas (4.5 equivalents) was introduced into the reaction mix-





Scheme 7.

compound **26** turned out to be of (*R,R*)-configuration which, of course, must apply to the corresponding stereocenters in the amidoalcohol **24** as well. Finally, according to these results the main product of the trapping reaction of the *N*-acyliminium ion **18** with the silylenolether **19**, **22** must have (*R*)-configuration at the newly created stereocenter at 2-position of the piperidine ring (Scheme 6) as well.

The  $^1\text{H}$  NMR spectra of the major isomer **20** and the minor isomer **21** from the trapping reaction of the *N*-acyliminium ion **15** with **19** were very similar to the major and minor isomer **22** and **23**, respectively, that had resulted from the corresponding reaction with the *N*-acyliminium ion **18**. Only the  $^1\text{H}$  NMR signals arising from the aryl groups, the phenyl and the naphthyl moiety, present in the chiral auxiliaries of **20/21** and **22/23**, differed, of course, significantly. Accordingly, the newly created stereocenter of the major isomer **20** and the minor isomer **21** was assigned (*R*)- and (*S*)-stereochemistry, respectively, based on the similarities with the major and minor isomers **22** and **23**.

In the next step, the amidoalkylation products **20/21** and **22/23** were transformed to the bicyclic enamides **27/31** and **29/33**. As starting materials, the mixtures of the diastereomeric amidoalkylation products were employed since the diastereomers of the cyclized products turned out to be easier to separate than those of the precursors. The cyclization was effected by heating the starting materials in the presence of molecular sieve and catalytic amounts of *p*-toluenesulfonic acid for 8 h to reflux. The pure diastereomers of the thus formed cyclic enamides **27/31** and **29/33** were obtained after column chromatography in yields of 21 %

(**27**), 25 % (**31**), 37 % (**29**), and 13 % (**33**), respectively (Scheme 7). As the compounds turned out to be unstable at r. t., which was likely to be a result of the enamide moiety present, they were quickly transformed to the saturated compounds which, indeed, appeared to be stable.

Interestingly, the reductions that had been accomplished by means of  $\text{NaBH}_4$  in acetic acid must have proceeded with high asymmetric induction, as in each case only a single diastereomer could be isolated, their yields amounting to 72 % (**28**), 43 % (**32**), 72 % (**30**), and 67 % (**34**), respectively. The last step of our synthetic sequence to pyrido[1,2-*c*]pyrimidinones required the removal of the chiral auxiliary from the nitrogen atom in 2-position of the ring system. This last step was only performed for compounds **28** and **32** which upon hydrogenation over Pd/C provided the desired target compounds **35** and **36** in 76 % and 68 % yield, respectively (Scheme 7).

The stereochemistry of the new stereocenter in the reduction products **28**, **30**, **32**, and **34** was assigned by means of  $^1\text{H}$  coupling constants observed in the  $^1\text{H}$  NMR spectra for the protons in positions 3, 4 and 4a in the bicyclic ring system. In addition, this assignment was further verified by NO experiments performed for the enantiopure target compound **35**. These experiments revealed positive NO effects between the protons in positions 3, 4a and 8 as indicated in Fig. 2. Of course, such effect would not be found in the (*R,S*)-configured isomer **37** as the distance between the protons in 3- and 4a-position is too large (Fig. 2). Taking into account the stereochemistry of the 4a-position identified by correlation with the aminoalcohol **26**,




Fig. 2. NOE experiments.

compound **35** must be of (*R,R*)- and its enantiomer **36** self-evidently of (*S,S*)-configuration.

## Conclusion

In the work presented, we demonstrated that “Asymmetric Electrophilic  $\alpha$ -Amidoalkylation” reactions can also be performed with piperidine derivatives provided with a carboxamide unit as a chiral auxiliary. The C-2 substituted piperidine derivatives obtained by utilizing this new type of asymmetric amidoalkylation reactions turned out to be well suited for the preparation of enantiopure pyrido[1,2-*c*]pyrimidinones, compounds with a core structure analogous to that of the natural products tetraopnerines.

## Experimental Section

All reactions were performed using dried glassware under  $N_2$  atmosphere. All solvents were freshly dried using standard [13] procedures. Melting points were determined on a Büchi melting point 510 apparatus and are uncorrected.  $^1H$  spectra were recorded in  $CDCl_3$  or  $CD_2Cl_2$  at 400 MHz. Infrared spectra were obtained on a Perkin-Elmer Paragon 1000 FTIR spectrometer. Microanalytical data for carbon, hydrogen and nitrogen were determined on a Heraeus Rapid Analyzer. Commercially obtained reagents were used without further purification. Flash chromatography was carried out using silica gel 60 (0.032–0.063 mm). HPLC: Merck Hitachi Series 6000, column: LiChrospher 250-4/250-25 Si 60 (5  $\mu$ m).

### General procedure for the reduction of the cyclic enamides (GPI)

The corresponding enamide was dissolved in glacial acetic acid, and  $NaBH_4$  was added at 0 °C. After 10 min the reaction mixture was allowed to warm to r. t. and stirred over night (16 h). The resulting solution was laced with  $H_2O$  and  $HCl$  (0.1 M) and extracted with  $CH_2Cl_2$ . The combined organic layers were dried ( $MgSO_4$ ) and concentrated *in vacuo*. The resulting crude product was purified by CC on silica gel (EtOAc / *n*-heptane 1 : 1).

### *N*-[(1*S*)-1-Phenylethyl]-3,6-dihydropyridine-1(2*H*)-carboxamide (**10**)

(*S*)-1-(1-Isocyanatoethyl)benzene (**8**) (4.91 g, 33.3 mmol) dissolved in THF (18 mL) was cooled to 0 °C, and 1,2,3,6-tetrahydropyridine (**9**) (5.54 g, 66.7 mmol) was added with stirring. After 10 min the mixture was warmed to r. t. and stirred for 13 h. The solvent was removed from the resulting mixture, and the remaining residue was dissolved in EtOAc and washed with aqueous  $NaHSO_4$  solution (3 $\times$ ) and  $H_2O$  (3 $\times$ ). The organic phase was dried over  $MgSO_4$  and concentrated *in vacuo*. The resulting residue was purified by CC on silica gel (EtOAc / *n*-heptane 1 : 1). Colorless crystals, 7.44 g (91 %). – M. p. 96–98 °C. –  $[\alpha]_D^{20} = -2.7^\circ$  ( $c = 0.075$ ,  $CHCl_3$ ). – IR (KBr):  $\nu = 3029, 2969, 2971, 2834, 1615, 1534, 1446, 1409, 1340, 1254, 762, 702, 653, 567, 532\text{ cm}^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.50$  (d,  $J = 6.7$  Hz, 3 H,  $HCCCH_3$ ), 2.13–2.19 (m, 2 H,  $NCH_2CH_2$ ), 3.47–3.52 (m, 2 H,  $NCH_2CH_2$ ), 3.80–3.83 (m, 2 H,  $NCH_2CH$ ), 4.59 (d,  $J = 6.7$  Hz, 1 H, *NH*), 5.06 (quin,  $J = 6.7$  Hz, 1 H,  $HCCCH_3$ ), 5.62–5.59 (m, 1 H,  $HC=CH$ ), 5.84–5.92 (m, 1 H,  $HC=CH$ ), 7.22–7.29 (m, 1 H,  $H_{ar}$ ), 7.29–7.37 (m, 4 H,  $H_{ar}$ ). – MS (EI):  $m/z = 230 [M]^+$ , 125, 105. –  $C_{14}H_{18}N_2O$  (230.31): calcd. C 73.01, H 7.88, N 12.16; found C 73.01, H 8.00, N 12.02.

### *N*-[(1*S*)-Naphthylethyl]-3,6-dihydropyridine-1(2*H*)-carboxamide (**12**)

Preparation according to **10** from (*S*)-1-(1-isocyanatoethyl)naphthalene (**11**) (0.473 mg, 2.39 mmol) in THF (20 mL) and **9** (0.397 mg, 4.80 mmol). Colorless crystals, 630 mg (94 %). – M. p. 153–155 °C. –  $[\alpha]_{578} = 35.0^\circ$  ( $c = 0.915$ ,  $CHCl_3$ ). – IR (KBr):  $\nu = 3320, 3050, 2981, 2917, 2833, 1610, 1534, 1407, 1252, 1214, 774, 665\text{ cm}^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.67$  (d,  $J = 6.8$  Hz, 3 H,  $HCCCH_3$ ), 2.14–2.17 (m, 2 H,  $NCH_2CH_2$ ), 3.47–3.50 (m, 2 H,  $NCH_2$ ), 3.70–3.85 (m, 2 H,  $NCH_2$ ), 4.63 (d,  $J = 7.3$  Hz, 1 H, *NH*), 5.59 (m, 1 H,  $HC=CH$ ), 5.82–5.89 (m, 2 H,  $HCCCH_3$ ,  $HC=CH$ ), 7.43–7.56 (m, 4 H,  $H_{ar}$ ), 7.77–7.79 (m, 1 H,  $H_{ar}$ ), 7.84–7.85 (m, 1 H,  $H_{ar}$ ), 8.17–8.19 (m, 1 H,  $H_{ar}$ ). – MS (EI):  $m/z = 280 [M]^+$ , 155, 127, 115. –  $C_{18}H_{20}N_2O$  (280.36): calcd. C 77.11, H 7.19, N 9.99; found C 77.18, H 7.20, N 9.91.

### *N*-[(1*S*)-1-Phenylethyl]-3,4-dihydropyridine-1(2*H*)-carboxamide (**13**)

In a pressure tube under  $N_2$ , a mixture of **10** (997 mg, 4.33 mmol) in THF (4 mL),  $NEt_3$  (1 mL) and Pd on  $\gamma-Al_2O_3$  (85 mg; 5 %) was heated to 105 °C for 4 h. After cooling to r. t., filtration and evaporation of the solvent the resulting residue was purified by CC on silica gel (EtOAc / *n*-heptane /  $CH_2Cl_2$  1 : 2 : 2). Colorless crystals, 813 mg (82 %). – M. p.

121–125 °C. –  $[\alpha]_{\text{D}}^{20} = 43.4^{\circ}$  ( $c = 2.015$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 2972, 1625, 1535, 1376, 1270, 986, 758, 698 \text{ cm}^{-1}$ . –  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.51$  (d,  $J = 6.9$  Hz, 3 H,  $\text{HCCH}_3$ ), 1.81–1.88 (m, 2 H,  $\text{NCH}_2\text{CH}_2$ ), 2.01–2.08 (m, 2 H,  $\text{NCH}_2\text{CH}_2\text{CH}_2$ ), 3.46–3.57 (m, 2 H,  $\text{NCH}_2$ ), 4.72 (d,  $J = 6.8$  Hz, 1 H,  $\text{NH}$ ), 4.88 (td,  $J = 4.0/8.2$  Hz, 1 H,  $\text{NCH}=\text{CH}$ ), 5.05 (quin,  $J = 6.9$  Hz, 1 H,  $\text{HCCH}_3$ ), 6.70 (d,  $J = 8.2$  Hz, 1 H,  $\text{NHC}=\text{CH}$ ), 7.25–7.27 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.32–7.37 (m, 4 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 230$   $[\text{M}]^+$ , 105. –  $\text{C}_{14}\text{H}_{18}\text{N}_2\text{O}$  (230.31): calcd. C 73.01, H 7.88, N 12.16; found C 72.85, H 8.06, N 12.15.

*N*-[(1*S*)-1-Naphthylethyl]-3,4-dihydropyridine-1(2*H*)-carboxamide (**16**)

Preparation according to **13** from **12** (720 mg, 2.57 mmol) in THF (4 mL),  $\text{NEt}_3$  (1 mL) and Pd on  $\gamma\text{-Al}_2\text{O}_3$  (85 mg; 5%). Purification by CC on silica gel (EtOAc / *n*-heptane 1 : 1). Colorless crystals, 485 mg (68%). – M. p. 148–151 °C. –  $[\alpha]_{\text{D}}^{20} = +109.3^{\circ}$  ( $c = 0.45$ ,  $\text{HCCl}_3$ ). – IR (KBr):  $\nu = 3049, 2932, 2872, 1634, 1538, 1454, 1373, 1353, 1268, 1254, 1188, 1070, 988, 800, 778, 736, 717 \text{ cm}^{-1}$ . –  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.69$  (d,  $J = 6.9$  Hz, 3 H,  $\text{HCCH}_3$ ), 1.82 (quin,  $J = 6.0$  Hz, 2 H,  $\text{NCH}_2\text{CH}_2$ ), 2.00–2.06 (m, 2 H,  $\text{NCH}=\text{CHCH}_2$ ), 3.49 (t,  $J = 5.6$  Hz, 2 H,  $\text{NCH}_2$ ), 4.76 (d,  $J = 7.2$  Hz, 1 H,  $\text{NH}$ ), 4.84 (td,  $J = 4.0/8.0$  Hz, 1 H,  $\text{NCH}=\text{CH}$ ), 5.86 (quin,  $J = 7.0$  Hz, 1 H,  $\text{HCCH}_3$ ), 6.69 (d,  $J = 8.0$  Hz, 1 H,  $\text{NCH}$ ), 7.43–7.58 (m, 4 H,  $\text{H}_{\text{ar}}$ ), 7.78–7.82 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.85–7.89 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 8.14–8.18 (m, 1 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 280$   $[\text{M}]^+$ , 155, 125, 105. –  $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}$  (280.36): calcd. C 77.11, H 7.19, N 9.99; found C 77.19, H 7.33, N 9.78.

(2*R*)-2-(2-Oxo-2-phenylethyl)-*N*-[(1*S*)-1-phenylethyl]piperidine-1-carboxamide (**20**) and (2*S*)-2-(2-oxo-2-phenylethyl)-*N*-[(1*S*)-1-phenylethyl]piperidine-1-carboxamide (**21**)

HCl gas (175 mL, 7.81 mmol) was dissolved in  $\text{CH}_2\text{Cl}_2$  (8 mL) at  $-87$  °C using a gas-tight syringe. A solution of **13** (400 mg, 1.73 mmol) in  $\text{CH}_2\text{Cl}_2$  (4.5 mL) was slowly added over a period of 30 min. The excess of HCl was removed at  $10^{-2}$  mbar and  $-60$  °C (2 h). After cooling to  $-87$  °C,  $\text{TiCl}_4$  (386 mg, 1.91 mmol) was added, and the resulting yellow solution was stirred for 50 min. Afterwards trimethyl(1-phenylvinyl)oxy)silane (**19**) (501 mg, 2.61 mmol) in  $\text{CH}_2\text{Cl}_2$  (2 mL) was added over a period of 15 min. The resulting mixture was stirred for 16 h at  $-87$  °C and quenched with  $\text{H}_2\text{O}$  (10 mL). After neutralization with  $\text{NaHCO}_3$  solution the aqueous layer was extracted with  $\text{CH}_2\text{Cl}_2$  (3 $\times$ ). The combined organic layers were dried over  $\text{MgSO}_4$  and concentrated *in vacuo*. Purification by CC on silica gel (EtOAc / *n*-heptane 4 : 6) yielded 450 mg (74%) of the mixture of diastereomers **20** and **21**, which were separated by prep. HPLC (EtOAc / *n*-heptane 4 : 6; 15 mL/min). Analytical

HPLC (EtOAc / *n*-heptane 4 : 6; 1.0 mL/min): d. s. **20/21** = 28.7/71.3.

**20**: Colorless crystals, 168 mg (43%). – M. p. 84–85 °C. –  $[\alpha]_{\text{D}}^{20} = 51.2^{\circ}$  ( $c = 0.44$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 3409, 3026, 2933, 2863, 1674, 1622, 1506, 1448, 1372, 1264, 1016, 752, 703 \text{ cm}^{-1}$ . –  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.44$ –1.80 (m, 6 H,  $\text{CH}_2$ ), 1.48 (d,  $J = 7.0$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.71 (dt,  $J = 3.0/13.3$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.00 (dd,  $J = 4.6/17.2$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 3.65 (dd,  $J = 8.0/17.2$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 4.20 (d<sub>br</sub>,  $J = 13.7$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 4.49–4.76 (m, 1 H,  $\text{NCH}$ ), 4.97 (quin,  $J = 7.0$  Hz, 1 H,  $\text{HCCH}_3$ ), 6.07 (d,  $J = 7$  Hz, 1 H,  $\text{NH}$ ), 7.22–7.28 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.33–7.38 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.40–7.44 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.47–7.53 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.59–7.64 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.99–8.03 (m, 2 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 350$   $[\text{M}]^+$ , 231, 202. –  $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_2$  (350.46): calcd. C 75.40, H 7.48, N 7.99; found C 75.44, H 7.46, N 7.97.

**21**: Colorless crystals, 69 mg (18%). – M. p. 85–87 °C. –  $[\alpha]_{\text{D}}^{20} = -8.1$  ( $c = 0.51$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 3340, 3062, 2929, 2858, 1681, 1633, 1520, 1448, 1373, 1266, 1018, 755, 698 \text{ cm}^{-1}$ . –  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.36$ –1.76 (m, 6 H,  $\text{CH}_2$ ), 1.44 (d,  $J = 6.8$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.62 (dt,  $J = 3.1/13.1$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 2.95 (dd,  $J = 5.2/16.8$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 3.46 (dd,  $J = 7.3/16.8$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 4.04 (d<sub>br</sub>,  $J = 13.1$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 4.64–4.71 (m, 1 H,  $\text{NCH}$ ), 4.86 (quin,  $J = 6.8$  Hz, 1 H,  $\text{HCCH}_3$ ), 5.86 (d,  $J = 6.8$  Hz, 1 H,  $\text{NH}$ ), 7.08–7.13 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.16–7.21 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.23–7.27 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.38–7.44 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.50–7.55 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.88–7.92 (m, 2 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 350$   $[\text{M}]^+$ , 231, 202. –  $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}_2$  (350.46): calcd. C 75.40, H 7.48, N 7.99; found C 75.36, H 7.40, N 7.99.

(2*R*)-*N*-[(1*S*)-1-Naphthylethyl]-2-(2-oxo-2-phenylethyl)-piperidine-1-carboxamide (**22**) and (2*S*)-*N*-[(1*S*)-1-naphthylethyl]-2-(2-oxo-2-phenylethyl)piperidine-1-carboxamide (**23**)

Preparation according to **20/21** from **16** (430 mg, 1.53 mmol) in  $\text{CH}_2\text{Cl}_2$  (4.5 mL), HCl gas (175 mL, 7.81 mmol) in  $\text{CH}_2\text{Cl}_2$  (8 mL),  $\text{TiCl}_4$  (387 mg, 2.04 mmol) and **19** (556 mg, 2.89 mmol). Purification by CC on silica gel (EtOAc / *n*-heptane 1 : 1) yielded 395 mg (58%) of the mixture of diastereomers **22** and **23**, which were separated by prep. HPLC (EtOAc / *n*-heptane 4 : 6; 15 mL/min). Analytical HPLC (EtOAc / *n*-heptane 4 : 6; 1.0 mL/min): d. s. **22/23** = 15.7/84.3.

**22**: Colorless crystals. – M. p. 163 °C. –  $[\alpha]_{578} = 120.8^{\circ}$  ( $c = 0.625$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 3350, 2940, 1680, 1630, 1510 \text{ cm}^{-1}$ . –  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.40$ –1.75 (m, 6 H,  $\text{CH}_2$ ), 1.64 (d,  $J = 6.9$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.72 (dt,  $J = 2.7/13.6$  Hz, 1 H,  $\text{NCH}_2$ ), 2.97 (dd,  $J = 4.4/17.2$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 3.66 (dd,  $J = 8.1/17.2$  Hz, 1 H,  $\text{CH}_2\text{CO}$ ), 4.18 (d<sub>br</sub>,  $J = 13.6$  Hz, 1 H,  $\text{NCH}_2$ ), 4.66–4.75 (m, 1 H,  $\text{NCH}$ ), 5.81

(quin,  $J = 6.9$  Hz, 1 H,  $HCCH_3$ ), 6.09 (d,  $J = 6.9$  Hz, 1 H, NH), 7.47–8.02 (m, 11 H,  $H_{ar}$ ), 8.21–8.23 (m, 1 H,  $H_{ar}$ ). – MS (EI):  $m/z = 400$   $[M]^+$ , 202, 155, 105. –  $C_{26}H_{28}N_2O_2$  (400.52): calcd. C 77.97, H 7.05, N 6.99; found C 78.08, H 7.18, N 6.84.

**23**: Colorless crystals. – M. p. 43 °C. –  $[\alpha]_{578} = 52.6^\circ$  ( $c = 0.38$ ,  $CHCl_3$ ). – IR (KBr):  $\nu = 3350, 2930, 2850, 1730, 1680, 1530$   $cm^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.40$ – $1.80$  (m, 6 H,  $CH_2$ ), 1.67 (d,  $J = 6.8$  Hz, 3 H,  $HCCH_3$ ), 2.73 (dt,  $J = 2.7/14.3$  Hz, 1 H,  $NCH_2$ ), 3.02 (dd,  $J = 5.7/16.7$  Hz, 1 H,  $CH_2CO$ ), 3.45 (dd,  $J = 7.1/16.7$  Hz, 1 H,  $CH_2CO$ ), 4.10 (d<sub>br</sub>,  $J = 14.3$  Hz, 1 H,  $NCH_2$ ), 4.66–4.75 (m, 1 H, NCH), 5.78 (quin,  $J = 7.0$  Hz, 1 H,  $HCCH_3$ ), 5.88 (d,  $J = 7.0$  Hz, 1 H, NH), 7.37–7.82 (m, 11 H,  $H_{ar}$ ), 8.12–8.15 (m, 1 H,  $H_{ar}$ ). – MS (EI):  $m/z = 400$   $[M]^+$ , 202, 155, 105. –  $C_{26}H_{28}N_2O_2$  (400.52): calcd. C 77.97, H 7.05, N 6.99; found C 78.15, H 7.21, N 6.79.

(2*R*)-2-[(2*R*)-2-Hydroxy-2-phenylethyl]-*N*-[(1*S*)-1-naphthylethyl]piperidine-1-carboxamide (**24**) and (2*R*)-2-[(2*S*)-2-hydroxy-2-phenylethyl]-*N*-[(1*S*)-1-naphthylethyl]piperidine-1-carboxamide (**25**)

$NaBH_4$  (56.8 mg, 1.5 mmol) was added to a solution of **23** (120.2 mg, 0.3 mmol) in EtOH (25 mL) at 0 °C and the mixture stirred for 15 h at r. t. and subsequently laced with HCl (2 M) and  $H_2O$  and extracted with  $Et_2O$  (3 $\times$ ). The combined organic layers were dried ( $MgSO_4$ ) and concentrated *in vacuo*. The resulting residue was purified by CC on silica gel (EtOAc / *n*-heptane 6 : 4). Separation with prep. HPLC (EtOAc / *n*-heptane 4 : 1; 13 mL/min) yielded **24** and **25**. Analytical HPLC (EtOAc / *n*-heptane 3 : 7; 2.0 mL/min; 35 °C): d. s. **24/25** = 66/34.

**24**: Colorless crystals, 63.3 mg (51.6 %). – M. p. 96 °C. –  $[\alpha]_{578} = 142.2^\circ$  ( $c = 0.225$ ,  $CHCl_3$ ). – IR (KBr):  $\nu = 3320, 2930, 2860, 1620, 1540$   $cm^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.25$ – $1.66$  (m, 6 H), 1.66 (d,  $J = 6.9$  Hz, 3 H,  $CH_3$ ), 1.90 (ddd,  $J = 4.2/10.1/14.3$  Hz, 1 H,  $CH_2CHOH$ ), 2.00 (ddd,  $J = 3.4/7.7/14.3$  Hz, 1 H,  $CH_2CHOH$ ), 2.66 (dt,  $J = 2.8/12.9$  Hz, 1 H,  $NCH_2ax.$ ), 3.17 (s<sub>br</sub>, 1 H,  $CHOH$ ), 3.83 (d,  $J = 12.9$  Hz, 1 H,  $NH_2eq.$ ), 4.20–4.23 (m, 1 H, NCH), 4.68 (d,  $J = 7.7$  Hz, 1 H,  $CHOH$ ), 5.43 (d,  $J = 6.9$  Hz, 1 H, NH), 5.87 (quint,  $J = 6.9$  Hz, 1 H,  $CHCH_3$ ), 7.24–7.37 (m, 4 H,  $H_{ar}$ ), 7.75–7.77 (m, 1 H,  $H_{ar}$ ), 7.84–7.86 (m, 1 H,  $H_{ar}$ ), 8.19–8.21 (m, 1 H,  $H_{ar}$ ). – MS (EI):  $m/z = 402$   $[M]^+$ . –  $C_{22}H_{26}N_2O$  (402.54): calcd. C 77.58, H 7.51, N 6.96; found C 77.63, H 7.64, N 6.81.

**25**: Colorless crystals, 27.8 mg (23 %). – M. p. 165 °C. –  $[\alpha]_{578} = 186.7^\circ$  ( $c = 0.15$ ,  $CHCl_3$ ). – IR (KBr):  $\nu = 3270, 2930, 2860, 1610, 1540$   $cm^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.39$ – $1.82$  (m, 7 H), 1.69 (d,  $J = 6.6$  Hz, 3 H,  $CH_3$ ), 2.19 (ddd,  $J = 2.2/12.1/14.3$  Hz, 1 H), 2.80 (t,  $J = 12.5$  Hz, 1 H,  $NCH_2ax.$ ), 3.52–3.72 (m<sub>br</sub>, 1 H,  $NCH_2eq.$ ), 4.51 (d,  $J = 11.0$  Hz, 1 H,  $CH-OH$ ), 4.68 (m, 1 H, NCH),

5.13 (s<sub>br</sub>, 1 H, NH), 5.92 (quint,  $J = 6.6$  Hz, 1 H,  $CH-CH_3$ ), 7.25–7.37 (m, 5 H,  $H_{ar}$ ), 7.43–7.55 (m, 4 H,  $H_{ar}$ ), 7.78–7.80 (m, 1 H,  $H_{ar}$ ), 7.83–7.87 (m, 1 H,  $H_{ar}$ ), 8.15–8.17 (m, 1 H,  $H_{ar}$ ). – MS (EI):  $m/z = 402$   $[M]^+$ . –  $C_{22}H_{26}N_2O$  (402.54): calcd. C 77.58, H 7.51, N 6.96; found C 77.56, H 7.59, N 6.88.

(1*R*)-1-Phenyl-2-[(2*R*)-piperidin-2-yl]ethanol (**26**) [12]

To a solution of **24** (80.5 mg, 0.2 mmol) in dioxane (10 mL) was added LiOH· $H_2O$  (209 mg, 5.00 mmol) in  $H_2O$  (1 mL) and the mixture stirred for 72 h at 150 °C in a pressure tube. After evaporation of the solvent the residue was laced with HCl solution and washed with  $Et_2O$ . The remaining aqueous solution was brought to pH = 9 with KOH and extracted with  $Et_2O$ . The combined organic layers were dried ( $MgSO_4$ ), concentrated *in vacuo* and recrystallized from *n*-hexane. Colorless crystals, 25.2 mg (61 %). –  $[\alpha]_{546} = 40.0^\circ$  ( $c = 0.175$ ,  $CHCl_3$ ). –  $[\alpha]_{578} = 34.3^\circ$  ( $c = 0.15$ ,  $CHCl_3$ ). –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.09$ – $1.19$  (m, 1 H), 1.28–1.39 (m, 1 H), 1.48–1.73 (m, 5 H), 1.81–1.87 (m, 1 H), 2.67 (ddd,  $J = 2.9/12.1/13.6$  Hz, 1 H,  $NCH_2ax.$ ), 2.92 (tt,  $J = 2.5/10.7$  Hz, 1 H, NCH), 3.09 (d,  $J = 13.6$  Hz, 1 H,  $NCH_2eq.$ ), 4.95 (dd,  $J = 2.6/10.6$  Hz, 1 H,  $CH-OH$ ), 7.21–7.38 (m, 5 H,  $H_{ar}$ ).

(4*aR*)-3-Phenyl-2-[(1*S*)-1-phenylethyl]-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**27**) and (4*aS*)-3-phenyl-2-[(1*S*)-1-phenylethyl]-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**31**)

A mixture of **20** and **21** (450 mg, 1.28 mmol) in toluene (10 mL) together with some crystals of *p*-toluenesulfonic acid and molecular sieve (600 mg) was heated to reflux for 8 h. After filtration the solution was washed with aqueous  $NaHCO_3$  solution (1 $\times$ ) and  $H_2O$  (3 $\times$ ) and dried over  $MgSO_4$ . Evaporation of the solvent gave a crude product which was purified by CC on silica gel (EtOAc / *n*-heptane 2 : 8). The diastereomers **27** and **31** were obtained by prep. HPLC (EtOAc / *n*-heptane 1 : 9; 14.4 mL/min).

**27**: Colorless oil (decomposition at r. t.), 89 mg (21 %). – IR (film):  $\nu = 3060, 2934, 2857, 1706, 1660, 1446, 1265, 1250, 1074, 1028, 756, 699$   $cm^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.16$ – $1.94$  (m, 6 H,  $CH_2$ ), 1.73 (d,  $J = 7.1$  Hz, 3 H,  $HCCH_3$ ), 2.43 (dt,  $J = 2.5/13.2$  Hz, 1 H,  $NCH_2ax.$ ), 4.82–4.85 (m, 1 H, NCH), 4.35 (d,  $J = 13.2$  Hz, 1 H,  $NCH_2eq.$ ), 4.64 (q,  $J = 7.1$  Hz, 1 H,  $HCCH_3$ ), 4.69 (d,  $J = 4.6$  Hz, 1 H,  $NC=CH$ ), 7.14–7.32 (m, 10 H,  $H_{ar}$ ). – MS (EI):  $m/z = 332$   $[M]^+$ , 227, 105. –  $C_{22}H_{24}N_2O$  (332.45): calcd. C 79.48, H 7.28, N 8.43; found C 79.37, H 7.38, N 7.84.

**31**: Colorless oil (decomposition at r. t.), 107 mg (25 %). – IR (film):  $\nu = 3060, 2937, 2857, 1710, 1660, 1446, 1268, 1250, 1074, 1028, 735, 699$   $cm^{-1}$ . –  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta = 1.21$ – $1.92$  (m, 6 H,  $CH_2$ ), 1.72 (d,  $J = 6.8$  Hz,

3 H,  $\text{HCCH}_3$ ), 2.45 (dt,  $J = 3.1/12.7$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.94 (td,  $J = 2.8/10.9$  Hz, 1 H,  $\text{NCH}$ ), 4.37 (d<sub>br</sub>,  $J = 13.0$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 4.67 (d,  $J = 3.1$  Hz, 1 H,  $\text{NC}=\text{CH}$ ), 4.74 (q,  $J = 7.1$  Hz, 1 H,  $\text{HCCH}_3$ ), 7.14–7.36 (m, 10 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 332$  [ $\text{M}]^+$ , 227, 105. –  $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}$  (332.45): calcd. C 79.48, H 7.28, N 8.43; found C 79.88, H 7.58, N 7.73.

(4*aR*)-2-[(1*S*)-1-Naphthylethyl]-3-phenyl-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**29**) and (4*aS*)-2-[(1*S*)-1-naphthylethyl]-3-phenyl-2,4*a*,5,6,7,8-hexahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**33**)

Preparation according to **27/31** from a mixture of **22** and **23** (361 mg, 0.90 mmol) in toluene (15 mL). Purification by CC on silica gel (EtOAc / *n*-heptane 2 : 8) and separation by prep. HPLC (EtOAc / *n*-heptane 4 : 6; 13.5 mL/min) yielded the diastereomers **29** and **33**.

**29**: Colorless oil (decomposition at r. t.), 127 mg (37 %). – IR (KBr):  $\nu = 3056, 2918, 2850, 1634, 1446, 1403, 1265, 1250, 738, 704$   $\text{cm}^{-1}$ . –  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.10$ – $1.85$  (m, 6 H,  $\text{CH}_2$ ), 1.78 (d,  $J = 7.4$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.46 (dt,  $J = 3.6/12.8$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.70 (td,  $J = 3.7/10.5$  Hz, 1 H,  $\text{NCH}$ ), 4.39 (d,  $J = 3.9$  Hz, 1 H,  $\text{NC}=\text{CH}$ ), 4.45 (d<sub>br</sub>,  $J = 12.8$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 5.92 (q,  $J = 7.4$  Hz, 1 H,  $\text{HCCH}_3$ ), 6.64–6.80 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 6.86–6.92 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 6.93–7.03 (m, 3 H,  $\text{H}_{\text{ar}}$ ), 7.05–7.12 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.34–7.45 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.53–7.58 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.72–7.76 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.89–7.94 (m, 1 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 382$  [ $\text{M}]^+$ , 227, 155. –  $\text{C}_{26}\text{H}_{26}\text{N}_2\text{O}$  (382.51): calcd. C 81.64, H 6.85, N 7.32; found C 81.93, H 6.85, N 7.03.

**33**: Colorless oil (decomposition at r. t.), 45 mg (13 %). – IR (KBr):  $\nu = 3052, 2935, 2854, 1658, 1644, 1446, 1403, 1263, 1250, 779, 761, 735, 703$   $\text{cm}^{-1}$ . –  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 1.04$  (dt,  $J = 3.7/11.8$  Hz, 1 H,  $\text{CH}_2$ ), 1.23–1.78 (m, 5 H,  $\text{CH}_2$ ), 1.89 (d,  $J = 6.9$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.64 (dt,  $J = 3.0/12.8$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.74 (td,  $J = 3.2/11.8$  Hz, 1 H,  $\text{NCH}$ ), 4.46 (d<sub>br</sub>,  $J = 13.1$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 4.50 (d,  $J = 3.5$  Hz, 1 H,  $\text{NC}=\text{CH}$ ), 5.92 (q,  $J = 6.9$  Hz, 1 H,  $\text{HCCH}_3$ ), 6.71–6.87 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 6.97–7.02 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.03–7.11 (m, 3 H,  $\text{H}_{\text{ar}}$ ), 7.14–7.21 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.43–7.53 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.61–7.67 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.80–7.85 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.91–7.97 (m, 1 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 382$  [ $\text{M}]^+$ , 227, 155. –  $\text{C}_{26}\text{H}_{26}\text{N}_2\text{O}$  (382.51): calcd. C 81.64, H 6.85, N 7.32; found C 81.99, H 6.94, N 6.89.

(3*R*,4*aR*)-3-Phenyl-2-[(1*S*)-1-phenylethyl]octahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**28**)

According to GP1 from **27** (50 mg, 0.15 mmol) in AcOH (4.5 mL) and  $\text{NaBH}_4$  (136 mg, 3.60 mmol). Colorless crystals, 36 mg (72 %). – M. p. 76–81 °C. –  $[\alpha]_{\text{D}}^{20} = 76.7$  ( $c = 0.08$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 2932, 2852, 1627, 1470, 1445, 1362, 1321, 1275, 1229, 1095, 1029, 747, 700$   $\text{cm}^{-1}$ . –  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 0.50$  (dq,  $J = 3.8/12.6$  Hz,

1 H,  $\text{CH}_2$ ), 0.88 (d,  $J = 13.1$  Hz, 1 H,  $\text{CH}_2$ ), 1.08–1.23 (m, 2 H,  $\text{CH}_2$ ), 1.27 (d,  $J = 7.2$  Hz, 3 H,  $\text{HCCH}_3$ ), 1.45–1.58 (m, 2 H,  $\text{CH}_2$ ), 1.73 (ddd,  $J = 1.7/3.2/13.5$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 1.98 (ddd,  $J = 5.4/8.3/13.4$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 2.53 (dt,  $J = 2.4/13.0$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.10 (ddt,  $J = 2.1/8.2/12.2$ , 1 H,  $\text{NCH}$ ), 4.24 (dd,  $J = 3.3/5.4$  Hz, 1 H,  $\text{NCH}(\text{Ph})$ ), 4.51 (td,  $J = 2.2/13.2$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 5.93 (q,  $J = 7.2$  Hz, 1 H,  $\text{HCCH}_3$ ), 7.13–7.31 (m, 10 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 334$  [ $\text{M}]^+$ , 229, 215, 132, 105. –  $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}$  (334.46): calcd. C 79.01, H 7.84, N 8.38; found C 79.01, H 7.91, N 8.31.

(3*S*,4*aS*)-3-Phenyl-2-[(1*S*)-1-phenylethyl]octahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**32**)

According to GP1 from **31** (56 mg, 0.17 mmol) in AcOH (5 mL) and  $\text{NaBH}_4$  (127 mg, 3.37 mmol). Colorless crystals, 168 mg (43 %). – M. p. 77–73. –  $[\alpha]_{\text{D}}^{20} = -111.9^\circ$  ( $c = 0.45$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 3030, 2934, 2853, 1633, 1470, 1445, 1365, 1329, 1278, 1095, 1029, 736, 699$   $\text{cm}^{-1}$ . –  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 0.87$ – $1.00$  (m, 1 H,  $\text{CH}_2$ ), 1.29–1.51 (m, 3 H,  $\text{CH}_2$ ), 1.72–1.80 (m, 2 H,  $\text{CH}_2$ ), 1.78 (d,  $J = 7.2$  Hz, 3 H,  $\text{HCCH}_3$ ), 2.12 (ddd,  $J = 5.8/6.7/13.6$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 2.43 (ddd,  $J = 5.1/6.0/13.6$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 2.66 (t,  $J = 12.9$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.23 (ddd,  $J = 2.6/5.7/11.9$  Hz, 1 H,  $\text{NCH}$ ), 4.62 (d<sub>br</sub>,  $J = 12.9$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 4.73 (dd,  $J = 5.2/6.7$  Hz, 1 H,  $\text{NCH}(\text{Ph})$ ), 5.41 (q,  $J = 7.2$  Hz, 1 H,  $\text{HCCH}_3$ ), 7.19–7.31 (m, 8 H,  $\text{H}_{\text{ar}}$ ), 7.37–7.52 (m, 2 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 334$  [ $\text{M}]^+$ , 229, 215, 132, 105. –  $\text{C}_{22}\text{H}_{26}\text{N}_2\text{O}$  (334.46): calcd. C 79.01, H 7.84, N 8.38; found C 79.08, H 7.84, N 8.32.

(3*R*,4*aR*)-2-[(1*S*)-1-Naphthylethyl]-3-phenyloctahydro-1*H*-pyrido[1,2-*c*]pyrimidin-1-one (**30**)

According to GP1 from **29** (80 mg, 0.21 mmol) in AcOH (7 mL) and  $\text{NaBH}_4$  (180 mg, 4.18 mmol). Colorless crystals, 58 mg (72 %). – M. p. 137–139. –  $[\alpha]_{\text{D}}^{20} = 5.8^\circ$  ( $c = 0.09$ ,  $\text{CHCl}_3$ ). – IR (KBr):  $\nu = 3050, 2936, 2854, 1622, 1472, 1447, 1277, 1228, 1191, 806, 783, 731, 701, 644$   $\text{cm}^{-1}$ . –  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta = 0.51$ – $0.63$  (m, 1 H,  $\text{NCHCH}_2$ ), 0.86–0.95 (m, 1 H,  $\text{NCHCH}_2$ ), 1.13–1.32 (m, 2 H,  $\text{CH}_2$ ), 1.47–1.63 (m, 2 H,  $\text{CH}_2$ ), 1.69 (d,  $J = 7.1$ , Hz, 3 H,  $\text{HCCH}_3$ ), 1.92 (ddd,  $J = 1.6/3.0/13.5$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 2.37 (ddd,  $J = 5.7/8.2/13.5$  Hz, 1 H,  $\text{NCH}(\text{Ph})\text{CH}_2$ ), 2.63 (dt,  $J = 3.0/13.2$  Hz, 1 H,  $\text{NCH}_2\text{ax.}$ ), 3.21 (ddt, 2.1/8.2/11.9 Hz, 1 H,  $\text{NCH}$ ), 4.55 (dd,  $J = 3.1/5.4$  Hz, 1 H,  $\text{NCH}(\text{Ph})$ ), 4.60 (,  $J = 13.2$  Hz, 1 H,  $\text{NCH}_2\text{eq.}$ ), 6.58–6.62 (m, 4 H,  $\text{H}_{\text{ar}}$ ), 6.65–6.72 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 6.77 (q,  $J = 7.1$ , 1 H,  $\text{HCCH}_3$ ), 7.13–7.19 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.35–7.41 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 7.42–7.47 (m, 1 H,  $\text{H}_{\text{ar}}$ ), 7.55–7.63 (m, 2 H,  $\text{H}_{\text{ar}}$ ), 8.63–8.68 (m, 1 H,  $\text{H}_{\text{ar}}$ ). – MS (EI):  $m/z = 384$  [ $\text{M}]^+$ , 229, 153, 127. –  $\text{C}_{26}\text{H}_{28}\text{N}_2\text{O}$  (384.52): calcd. C 81.21, H 7.34, N 7.29; found C 81.13, H 7.33, N 7.20.

*(3S,4aS)-2-[(1S)-1-Naphthylethyl]-3-phenyloctahydro-1H-pyrido[1,2-*c*]pyrimidin-1-one (34)*

According to GP1 from **33** (25 mg, 0.07 mmol) in AcOH (3 mL) and NaBH<sub>4</sub> (49 mg, 1.31 mmol). Colorless oil, 18 mg (67%). –  $[\alpha]_{\text{D}}^{20} = 66.5^{\circ}$  ( $c = 1.24$ , CHCl<sub>3</sub>). – IR (KBr):  $\nu = 3050, 2936, 2854, 1622, 1472, 1447, 1277, 1228, 1191, 806, 783, 731, 701, 644 \text{ cm}^{-1}$ . – <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 0.43$  (dq,  $J = 3.7/12.3 \text{ Hz}$ , 1 H, CH<sub>2</sub>), 0.71–0.83 (m, 1 H, CH<sub>2</sub>), 1.01–1.27 (m, 2 H, CH<sub>2</sub>), 1.40–1.48 (m, 3 H, CH<sub>2</sub>), 1.45 (d,  $J = 7.0 \text{ Hz}$ , 3 H, HCCCH<sub>3</sub>), 1.52 (d<sub>br</sub>,  $J = 13.4 \text{ Hz}$ , 1 H, CH<sub>2</sub>), 2.58 (dt,  $J = 2.7/12.9 \text{ Hz}$ , 1 H, NCH<sub>2</sub>ax.), 2.88 (tt,  $J = 3.6/6.3 \text{ Hz}$ , 1 H, NCH), 4.01 (t,  $J = 4.4 \text{ Hz}$ , 1 H, NCH(Ph)CH<sub>2</sub>), 4.55 (d<sub>br</sub>,  $J = 12.9 \text{ Hz}$ , 1 H, NCH<sub>2</sub>eq.), 6.51 (q,  $J = 7.0 \text{ Hz}$ , 1 H, HCCCH<sub>3</sub>), 7.05–7.10 (m, 2 H, H<sub>ar</sub>), 7.12–7.24 (m, 3 H, H<sub>ar</sub>), 7.25–7.29 (m, 1 H, H<sub>ar</sub>), 7.32–7.37 (m, 1 H, H<sub>ar</sub>), 7.40–7.52 (m, 2 H, H<sub>ar</sub>), 7.72–7.77 (m, 1 H, H<sub>ar</sub>), 7.78–7.83 (m, 1 H, H<sub>ar</sub>), 8.01–8.06 (m, 1 H, H<sub>ar</sub>). – MS (EI):  $m/z = 384$  [M]<sup>+</sup>, 229, 153, 127. – C<sub>26</sub>H<sub>28</sub>N<sub>2</sub>O (384.52): calcd. C 81.21, H 7.34, N 7.29; found C 81.23, H 7.26, N 7.25.

*(3R,4aR)-3-Phenyloctahydro-1H-pyrido[1,2-*c*]pyrimidin-1-one (35)*

A mixture of **28** (0.32 mg, 0.10 mmol) and Pd/C (10 mg; 10%) in MeOH (25 mL) was stirred at r.t. under hydrogen for 14 h. After filtration and removal of the solvent *in vacuo*

the residue was purified by CC on silica gel (EtOAc / *n*-heptane 3 : 7). Colorless crystals, 15 mg (68%). – M.p. 176–178 °C. –  $[\alpha]_{\text{D}}^{20} = -64.3^{\circ}$  ( $c = 0.3$ , CHCl<sub>3</sub>). – IR (KBr):  $\nu = 3192, 2920, 2852, 1644, 1472, 1453, 1362, 1333, 1289, 1264, 1131, 1100, 757, 698 \text{ cm}^{-1}$ . – <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta = 1.15$ –1.29 (m, 1 H, CH<sub>2</sub>), 1.29–1.51 (m, 2 H, CH<sub>2</sub>), 1.69–1.87 (m, 4 H, CH<sub>2</sub>), 2.13 (dtd,  $J = 2.2/3.5/13.3 \text{ Hz}$ , 1 H, NCH(Ph)CH<sub>2</sub>), 2.58 (dt,  $J = 3.3/13.1 \text{ Hz}$ , 1 H, NCH<sub>2</sub>ax.), 3.30 (ddt,  $J = 3.0/3.9/11.2 \text{ Hz}$ , 1 H, NCH), 4.47 (dd,  $J = 3.0/11.5 \text{ Hz}$ , 1 H, NCH(Ph)), 4.50–4.58 (m, 1 H, NCH<sub>2</sub>eq.), 4.70 (s, 1 H, NH), 7.28–7.40 (m, 5 H, H<sub>ar</sub>). – MS (CI):  $m/z = 231$  [M+1]<sup>+</sup>. – C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O (230.31): calcd. C 73.01, H 7.88, N 12.16; found C 73.15, H 7.93, N 12.28.

*(3S,4aS)-3-Phenyloctahydro-1H-pyrido[1,2-*c*]pyrimidin-1-one (36)*

A mixture of **32** (0.38 mg, 0.11 mmol) and Pd/C (10 mg; 10%) in MeOH (20 mL) was stirred at r.t. under hydrogen for 14 h. After filtration and removal of the solvent *in vacuo* the residue was purified by CC on silica gel (EtOAc / *n*-heptane 3 : 7). The spectroscopic data were identical with those of **35**. Colorless crystals, 19 mg (76%). – M.p. 176–178 °C. –  $[\alpha]_{\text{D}}^{20} = 64.3$  ( $c = 0.35$ , CHCl<sub>3</sub>). – C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O (230.31): calcd. C 73.01, H 7.88, N 12.16; found C 73.18, H 7.97, N 11.90.

- [1] a) For recent examples, see: D. R. Ijzendoorn, P. N. M. Botman, R. H. Blaauw, *Org. Lett.* **2006**, *8*, 239–242; b) B. Dhudshia, B. F. T. Cooper, C. L. B. Macdonald, A. N. Thadani, *Chem. Commun. (Camb)* **2009**, *4*, 463–465; c) C. Yue, I. Gauthier, J. Royer, H.-P. Husson, *J. Org. Chem.* **1996**, *61*, 4949–4954.
- [2] For a review see: S. Källström, R. Leino, *Bioorg. Med. Chem.* **2008**, *16*, 601–635.
- [3] a) P. Q. Huang, *Synlett* **2006**, *8*, 1133–1149; b) C. Escolano, M. Amat, J. Bosch, *Chem-Eur J.* **2006**, *12*, 8198–8207; c) C. D. Risi, G. Fanton, G. P. Pollini, C. Trapella, F. Valente, V. Zanirato, *Tetrahedron: Asymmetry* **2008**, *19*, 131–155; d) P. Zhou, B.-C. Chen, F. A. Davis, *Tetrahedron* **2004**, *60*, 8003–8030.
- [4] K. T. Wanner, A. Kärtner, *Heterocycles* **1987**, *26*, 921–924.
- [5] K. T. Wanner, F. F. Paintner, *Tetrahedron* **1994**, *50*, 3113–3122.
- [6] G. Hoefner, G. Fuelep, K. T. Wanner, WO00140645, **2000**.
- [7] M. Ludwig, K. Polborn, K. T. Wanner, *Heterocycles* **2003**, *61*, 299–326.
- [8] U. Weber, C. Hoesl, W. Ponikwar, M. Suter, H. Nöth, K. T. Wanner, *Heterocycles* **2004**, *63*, 2747–2767.
- [9] a) H. M. Garraffo, T. F. Spande, P. Jain, T. Kaneko, T. H. Jones, M. S. Blum, T. M. Ali, R. R. Snelling, L. A. Isbell, H. G. Robertson, J. W. Daly, *Rapid. Commun. Mass. Spectrom.* **2001**, *15*, 1409–1415; b) A. B. Charette, S. Mathieu, J. Martel, *Org. Lett.* **2005**, *7*, 5401–5404.
- [10] J. Streith, A. Boiron, J.-L. Paillaud, E.-M. Rodriguez-Perez, C. Strehler, T. Tschamber, M. Zehnder, *Helv. Chim. Acta* **1995**, *78*, 61–72.
- [11] a) K. T. Wanner, A. Kärtner, *Arch. Pharm. (Weinheim, Ger.)* **1987**, *320*, 1253–1267; b) R. Kammler, K. Polborn, K. T. Wanner, *Tetrahedron* **2003**, *59*, 3359–3368; c) K. T. Wanner, E. Wadenstorfer, A. Kärtner, *Synlett* **1991**, *11*, 797–799.
- [12] C. Schöpf, G. Dummer, Th. Kaufmann, R. Kress, *Liebigs Ann. Chem.* **1959**, 628, 101.
- [13] D. D. Perrin, W. L. F. Armarego, *Purification of Laboratory Chemicals*, Vol. 3, Pergamon, New York, **1988**.